Get started
Spyre Therapeutics, Inc.Spyre Therapeutics, Inc.Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc.

No trades
OverviewFinancialsNewsDocumentsCommunityTechnicalsForecastsSeasonalsOptionsETFs
Full chart
Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪7.02 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.36 USD
Net income (FY)
‪−126.54 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪77.42 M‬
Beta (1Y)
1.86

Employees


Employees (FY)
102
Change (1Y)
+37 +56.92%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.24 M‬ USD

About Spyre Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Cameron Turtle
Website
spyre.com
Headquarters
Waltham
Founded
2013
IPO date
Apr 7, 2016
Identifiers
3
ISIN US00773J2024
CFI code
ESVUFR
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Check out other big names from the same industry as SYRE.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


VTI
Vanguard Total Stock Market ETF
Weight 0.01%
Market value ‪181.99 M‬
IWM
iShares Russell 2000 Index Fund
Weight 0.18%
Market value ‪142.60 M‬
XBI
State Street SPDR S&P Biotech ETF
Weight 1.19%
Market value ‪96.21 M‬
VXF
Vanguard Extended Market ETF
Weight 0.07%
Market value ‪62.96 M‬
IBB
iShares Biotechnology ETF
Weight 0.57%
Market value ‪45.88 M‬
IWO
iShares Russell 2000 Growth Fund
Weight 0.23%
Market value ‪33.25 M‬
SCHA
Schwab U.S. Small-Cap ETF
Weight 0.13%
Market value ‪29.16 M‬
VTWO
Vanguard Russell 2000 ETF
Weight 0.17%
Market value ‪28.10 M‬
IWN
iShares Russell 2000 Value ETF
Weight 0.12%
Market value ‪17.24 M‬
VHT
Vanguard Health Care ETF
Weight 0.06%
Market value ‪10.94 M‬
ZPRR
State Street SPDR RUSSELL 2000 U.S. SMALL CAP UCITS ETF Accum Ptg USD
Weight 0.17%
Market value ‪9.72 M‬

Explore more ETFs 

Frequently asked questions


The current price of SYRE is 80.79 USD — it has increased by 0.02% in the past 24 hours. Watch Spyre Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Spyre Therapeutics, Inc. stocks are traded under the ticker SYRE.
SYRE stock has risen by 3.88% compared to the previous week, the month change is a 6.74% rise, over the last year Spyre Therapeutics, Inc. has showed a 357.22% increase.
We've gathered analysts' opinions on Spyre Therapeutics, Inc. future price: according to them, SYRE price has a max estimate of 115.00 USD and a min estimate of 78.00 USD. Watch SYRE chart and read a more detailed Spyre Therapeutics, Inc. stock forecast: see what analysts think of Spyre Therapeutics, Inc. and suggest that you do with its stocks.
SYRE reached its all-time high on Apr 8, 2016 with the price of 318.75 USD, and its all-time low was 2.66 USD and was reached on Jun 21, 2023. View more price dynamics on SYRE chart.
See other stocks reaching their highest and lowest prices.
SYRE stock is 4.60% volatile and has beta coefficient of 1.86. Track Spyre Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Spyre Therapeutics, Inc. there?
Today Spyre Therapeutics, Inc. has the market capitalization of ‪7.02 B‬, it has increased by 2.41% over the last week.
Yes, you can track Spyre Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Spyre Therapeutics, Inc. is going to release the next earnings report on Aug 6, 2026. Keep track of upcoming events with our Earnings Calendar.
SYRE earnings for the last quarter are −0.74 USD per share, whereas the estimation was −0.67 USD resulting in a −11.17% surprise. The estimated earnings for the next quarter are −0.73 USD per share. See more details about Spyre Therapeutics, Inc. earnings.
Spyre Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
SYRE net income for the last quarter is ‪−69.00 M‬ USD, while the quarter before that showed ‪−51.83 M‬ USD of net income which accounts for 0.00% change. Track more Spyre Therapeutics, Inc. financial stats to get the full picture.
No, SYRE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 14, 2026, the company has 102 employees. See our rating of the largest employees — is Spyre Therapeutics, Inc. on this list?
Like other stocks, SYRE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Spyre Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Spyre Therapeutics, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Spyre Therapeutics, Inc. stock shows the buy signal. See more of Spyre Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.